Literature DB >> 32951070

Sleep variability, 6-sulfatoxymelatonin, and diabetic retinopathy.

Supamas Sirisreetreerux1, Tharikarn Sujirakul2, Hataikarn Nimitphong1, Sittichai Pinyopodjanard1, Sunee Saetung1, La-Or Chailurkit1, Naricha Chirakalwasan3,4, Ben S Gerber5, Sirimon Reutrakul6,7.   

Abstract

PURPOSE: Recent evidence suggests that diabetic retinopathy (DR) is associated with abnormal melatonin regulation, possibly related to dysfunction of the melanopsin-expressing intrinsically photosensitive retinal ganglion cells. This study explored melatonin regulation in type 2 diabetes (T2D) patients with DR and its relation to sleep and circadian functioning.
METHODS: Thirty-five participants (10 non-diabetic controls, 10 T2D without DR, and 15 T2D with DR) were recruited. Overnight urine 6-sulfatoxymelatonin (aMT6s) and objective sleep and wrist activity (7-day actigraphy) were obtained.
RESULTS: After adjusting for covariates, having T2D with DR was significantly associated with lower urinary aMT6s (β = - 1.369, p = 0.004) compared with controls, while having T2D without DR was not (p = 0.418). T2D patients with DR reported poorer sleep quality (p = 0.014) and had greater variability of sleep duration (p = 0.017) than others, while no differences were found in sleep duration, efficiency, and rest-activity rhythm. After adjusting for covariates, lower nocturnal aMT6s was significantly associated with greater sleep variability.
CONCLUSION: T2D patients with DR exhibited low overnight production of aMT6s which likely contributed to sleep irregularities possibly due to weak circadian signaling. Whether or not melatonin supplementation could improve health in T2D patients with DR remains to be explored.

Entities:  

Keywords:  6-Sulfatoxymelatonin; Diabetes; Retinopathy; Sleep variability

Mesh:

Substances:

Year:  2020        PMID: 32951070     DOI: 10.1007/s11325-020-02165-3

Source DB:  PubMed          Journal:  Sleep Breath        ISSN: 1520-9512            Impact factor:   2.816


  19 in total

Review 1.  Diabetic retinopathy is a neurodegenerative disorder.

Authors:  Stephanie K Lynch; Michael D Abràmoff
Journal:  Vision Res       Date:  2017-04-28       Impact factor: 1.886

2.  Urinary 6-sulfatoxymelatonin level in diabetic retinopathy patients with type 2 diabetes.

Authors:  Wei Chen; Hui Cao; Qian-Yi Lu; Na Wang; Shu-Zhi Zhao; Xun Xu; Zhi Zheng
Journal:  Int J Clin Exp Pathol       Date:  2014-06-15

3.  Risk factors for high-risk proliferative diabetic retinopathy and severe visual loss: Early Treatment Diabetic Retinopathy Study Report #18.

Authors:  M D Davis; M R Fisher; R E Gangnon; F Barton; L M Aiello; E Y Chew; F L Ferris; G L Knatterud
Journal:  Invest Ophthalmol Vis Sci       Date:  1998-02       Impact factor: 4.799

4.  The associations of objectively measured sleep duration and sleep disturbances with diabetic retinopathy.

Authors:  Merwyn Chew; Nicholas Y Q Tan; Ecosse Lamoureux; Ching-Yu Cheng; Tien Yin Wong; Charumathi Sabanayagam
Journal:  Diabetes Res Clin Pract       Date:  2019-12-02       Impact factor: 5.602

5.  Assessment of diurnal melatonin, cortisol, activity, and sleep-wake cycle in patients with and without diabetic retinopathy.

Authors:  Shakoor Ba-Ali; Adam Elias Brøndsted; Henrik Ullits Andersen; Birgit Sander; Poul Jørgen Jennum; Henrik Lund-Andersen
Journal:  Sleep Med       Date:  2018-10-31       Impact factor: 3.492

6.  Associations between nocturnal urinary 6-sulfatoxymelatonin, obstructive sleep apnea severity and glycemic control in type 2 diabetes.

Authors:  Sirimon Reutrakul; Nantaporn Siwasaranond; Hataikarn Nimitphong; Sunee Saetung; Naricha Chirakalwasan; La-Or Chailurkit; Kriangsuk Srijaruskul; Boonsong Ongphiphadhanakul; Ammarin Thakkinstian
Journal:  Chronobiol Int       Date:  2017-01-27       Impact factor: 2.877

7.  Comparison of the effects of acute fluvoxamine and desipramine administration on melatonin and cortisol production in humans.

Authors:  D J Skene; C J Bojkowski; J Arendt
Journal:  Br J Clin Pharmacol       Date:  1994-02       Impact factor: 4.335

8.  Alteration of melatonin secretion in patients with type 2 diabetes and proliferative diabetic retinopathy.

Authors:  Taiichi Hikichi; Naohiro Tateda; Toshiaki Miura
Journal:  Clin Ophthalmol       Date:  2011-05-19

9.  Pupillary responses in non-proliferative diabetic retinopathy.

Authors:  Jason C Park; Yi-Fan Chen; Norman P Blair; Felix Y Chau; Jennifer I Lim; Yannek I Leiderman; Mahnaz Shahidi; J Jason McAnany
Journal:  Sci Rep       Date:  2017-03-23       Impact factor: 4.379

10.  Relationship between Intrinsically Photosensitive Ganglion Cell Function and Circadian Regulation in Diabetic Retinopathy.

Authors:  Sirimon Reutrakul; Stephanie J Crowley; Jason C Park; Felix Y Chau; Medha Priyadarshini; Erin C Hanlon; Kirstie K Danielson; Ben S Gerber; Tracy Baynard; Jade J Yeh; J Jason McAnany
Journal:  Sci Rep       Date:  2020-01-31       Impact factor: 4.379

View more
  4 in total

Review 1.  Effects of Melatonin on Diabetic Neuropathy and Retinopathy.

Authors:  Klausen Oliveira-Abreu; José Cipolla-Neto; Jose Henrique Leal-Cardoso
Journal:  Int J Mol Sci       Date:  2021-12-22       Impact factor: 5.923

2.  Effectiveness of emotional freedom techniques (EFT) vs sleep hygiene education group therapy (SHE) in management of sleep disorders among elderly.

Authors:  Nagwa Souilm; Nancy Mahmoud Elsakhy; Yasir A Alotaibi; Safaa Abdelazem Osman Ali
Journal:  Sci Rep       Date:  2022-04-20       Impact factor: 4.996

3.  Meta-Analysis of Relationship of Sleep Quality and Duration With Risk of Diabetic Retinopathy.

Authors:  Zhenzhen Zheng; Chaoyu Wang; Chunhe Li; Qinglan Wu; Xiaojuan Chen; Huimin Chen; Huizhao Liao; Jinru Zhu; Junyan Lin; Xudong Ou; Zhihong Zou; Jinhua Liang; Riken Chen
Journal:  Front Endocrinol (Lausanne)       Date:  2022-06-22       Impact factor: 6.055

4.  Investigation on the expression regulation of RIPK1/RIPK3 in the retinal ganglion cells (RGCs) cultured in high glucose.

Authors:  Sheng Gao; Xi Huang; Yi Zhang; Li Bao; Xiaoyue Wang; Meixia Zhang
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.